Related Experiment Video

Updated: Jun 13, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies

Kimberlee Burckart1, Sorin Beca, Randall J Urban

  • 1Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555-0460, USA.

Current Opinion in Clinical Nutrition and Metabolic Care
|May 18, 2010
PubMed
Abstract

Insights

Cancer cachexia causes muscle loss and death. Combined androgen and amino acid therapies may enhance muscle protein synthesis and reduce breakdown, potentially reversing this condition.

Area of Science:

  • Oncology
  • Metabolism
  • Muscle Physiology

Background:

  • Cancer cachexia is a significant cause of mortality, affecting millions globally.
  • It severely impacts patient quality of life and is inversely correlated with survival.
  • The precise mechanisms driving cancer-induced muscle wasting are still under investigation.

Purpose of the Study:

  • To review the pathogenesis of cancer-related muscle wasting.
  • To discuss potential interventions for reversing or preventing cancer cachexia.
  • To explore targeted anabolic therapies for muscle preservation.

Main Methods:

  • Review of existing literature on cancer cachexia mechanisms.
  • Analysis of cytokine signaling pathways (e.g., TNF-alpha, NF-kappaB).
  • Evaluation of therapeutic interventions including androgens and amino acids.

Main Results:

  • Cytokines like tumor necrosis factor-alpha activate muscle proteolysis via the ubiquitin-proteasome system.
  • Androgen treatment can reduce inflammatory cytokines and promote anti-inflammatory cytokines.
  • Amino acid supplementation has demonstrated the ability to induce muscle protein synthesis.

Conclusions:

  • Combined androgen and amino acid therapies show promise for enhancing muscle protein synthesis and reducing breakdown.
  • Further clinical studies are necessary to identify muscle-specific targets and biomarkers.
  • Developing targeted anabolic therapies is crucial for managing cancer cachexia.

More Related Videos

A Preclinical Model of Sepsis-Induced Myopathy with Disuse in Mice04:01

A Preclinical Model of Sepsis-Induced Myopathy with Disuse in Mice

Published on: June 14, 2024

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...